- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 31.10. | Compass points to job cuts as it defers trial readouts | ||
| 31.10. | Lexeo shares dip on early data with Alzheimer's gene therapy | ||
| 31.10. | Nasdaq debutante Septerna swells its IPO to $331m | ||
| 31.10. | Alpha-9's $175m third-round heads latest biotech financings | ||
| 31.10. | AZ confirms its China president is under investigation | ||
| 30.10. | UK Chancellor pledges £22bn rise in day-to-day NHS spending | ||
| 30.10. | Novartis gets FDA okay for frontline use of Scemblix in CML | ||
| 30.10. | Eledon drug helps transplants 'cure' type 1 diabetes | ||
| 30.10. | Alarm bell rings for GSK as US policy dents RSV jab sales | ||
| 30.10. | Lilly touts new Kisunla regimen that reduces side effects | ||
| 30.10. | Pfizer rebuffs Starboard criticism as it raises forecasts | ||
| 29.10. | Joy as NICE lifts restrictions on myeloma drug Elrexfio | ||
| 29.10. | AbbVie gets bigger in Alzheimer's R&D with Aliada takeover | ||
| 29.10. | Novartis pays $150m upfront for Monte Rosa degrader drug | ||
| 29.10. | NHS funding boost confirmed ahead of tomorrow's Budget | ||
| 29.10. | PHTI review of digital hypertension tools gives mixed results | ||
| 28.10. | MSD, Moderna start phase 3 adjuvant lung cancer trial | ||
| 28.10. | Astellas pulls geographic atrophy drug filing in the EU | ||
| 28.10. | Biogen shows its IgAN hand with felzartamab data | ||
| 28.10. | Novartis eyes year-end filing in US for Fabhalta in C3G | ||
| 28.10. | Apple wins in Masimo lawsuit, but its a shallow victory | ||
| 25.10. | GSK plans $800m US manufacturing investment | ||
| 25.10. | MSD buys Modifi for $1.3bn to boost oncology pipeline | ||
| 25.10. | Intellia trumpets CRISPR drug data, but shares fall | ||
| 25.10. | NICE backs two AIs for remote heart failure monitoring |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
